Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. New approaches to cancer care in a COVID-19 world

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Angelo Di Leo
  • Christine Desmedt
  • John M S Bartlett
  • Fanny Piette
  • Bent Ejlertsen
  • Kathleen I Pritchard
  • Denis Larsimont
  • Christopher Poole
  • Jorma Isola
  • Helena Earl
  • Henning Mouridsen
  • Frances P O'Malley
  • Fatima Cardoso
  • Minna Tanner
  • Alison Munro
  • Chris J Twelves
  • Christos Sotiriou
  • Lois Shepherd
  • David Cameron
  • Martine J Piccart
  • Marc Buyse
  • HER2/TOP2A Meta-analysis Study Group
Vis graf over relationer
Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer.
OriginalsprogEngelsk
TidsskriftLancet Oncology
Vol/bind12
Udgave nummer12
Sider (fra-til)1134-42
Antal sider9
ISSN1470-2045
DOI
StatusUdgivet - nov. 2011

ID: 33268143